These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 22847439)

  • 1. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
    Leontieva OV; Blagosklonny MV
    Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.
    Leontieva OV; Demidenko ZN; Gudkov AV; Blagosklonny MV
    PLoS One; 2011; 6(10):e26126. PubMed ID: 22022534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
    Korotchkina LG; Leontieva OV; Bukreeva EI; Demidenko ZN; Gudkov AV; Blagosklonny MV
    Aging (Albany NY); 2010 Jun; 2(6):344-52. PubMed ID: 20606252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical suppression of cellular senescence by p53.
    Demidenko ZN; Korotchkina LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9660-4. PubMed ID: 20457898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weak p53 permits senescence during cell cycle arrest.
    Leontieva OV; Gudkov AV; Blagosklonny MV
    Cell Cycle; 2010 Nov; 9(21):4323-7. PubMed ID: 21051933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
    Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation between p21 and Akt is required for p53-dependent cellular senescence.
    Kim YY; Jee HJ; Um JH; Kim YM; Bae SS; Yun J
    Aging Cell; 2017 Oct; 16(5):1094-1103. PubMed ID: 28691365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and gerosuppression: the mTOR saga continues.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2012 Nov; 11(21):3926-31. PubMed ID: 22987149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
    Shen H; Maki CG
    J Biol Chem; 2010 Jul; 285(30):23105-14. PubMed ID: 20489208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8832-7. PubMed ID: 24889617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
    Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
    Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of replicative senescence by rapamycin in rodent embryonic cells.
    Pospelova TV; Leontieva OV; Bykova TV; Zubova SG; Pospelov VA; Blagosklonny MV
    Cell Cycle; 2012 Jun; 11(12):2402-7. PubMed ID: 22672902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S6K in geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A.
    Korotchkina LG; Demidenko ZN; Gudkov AV; Blagosklonny MV
    Cell Cycle; 2009 Nov; 8(22):3777-81. PubMed ID: 19855165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.